List view / Grid view
In this episode, we explore our understanding of DNA and its implications for health outcomes. Additionally, we discuss the transition from DNA sequencing to actionable insights in medicine, contrasting genetics-driven drug discovery with traditional methods. Finally, we examine the evolving landscape of genetic technology and its potential impact on the…
Topological defects in mesenchymal stromal cell self-assembly could suggest their potential for cartilage regeneration.
In this Q&A, Celularity’s CEO and founder Dr Robert Hariri details the preclinical research that indicates that placenta-derived unmodified NK cells and genetically modified NK cells can target and selectively eliminate cells expressing stress ligands.
In this Q&A, senior leaders at Caris Life Sciences discuss how the company is advancing precision medicine by integrating ADCs into patient-specific cancer treatment plans, focusing on novel target discovery through comprehensive molecular profiling and clinico-genomic data.
This is the first study to demonstrate that a specific set of HERVs expressed in the human brain contribute to disorders like schizophrenia.
Neuroscientists are increasingly viewing disorders of the brain through the lens of the underlying molecular mechanisms as sometimes illuminated by genetic variants, rather than classifying disorders based solely on the clinical symptoms. The next step in the evolution of antiseizure medication will likely come from studying these molecular determinants of…
The discovery that omental fat has a mechanism to limit adipocyte formation may lead to new treatments for obesity and metabolic disease.
A panel of HTS assays was developed using the Transcreener platform to accelerate the development of selective helicase inhibitors.
AptaFluor SAH: A Homogenous, Universal Assay for Histone, RNA, & DNA Methyltransferases. Case Study for PRMT5, MLL4, METTL3/14, & NSP14
In this Q&A, Debiopharm’s Principal Scientist Dr Luke Piggott defines the critical requirement of biomarkers for identifying rare diseases. He illuminates how AI-enhanced approaches are accelerating the drug discovery process, particularly regarding clinical trial enrolment, and the breakthroughs he hopes to see in the future.
Four previously unknown genetic variants provide a new understanding of differences in risk between individuals of varying ancestries.
Stem-cell based blastocyst models have enabled scientists to redefine the molecular signature and timing of the onset of gastrulation.
The proof-of-concept study could lead to a cure for HIV that inactivates diverse strains across multiple cellular contexts.
14 March 2024 | By Drug Target Review
Join us for this webinar as we explore the role of organoids in advancing treatment of neurological disorders. Organoids, miniature 3D models of human organs, are at the forefront of neuroscience research, offering insights into the complexities of the human brain. In this webinar, esteemed experts will explore the latest…
A lab generated monoclonal antibody prevented EBV infection and EBV lymphomas in rodent models and could have future clinical applications.
